Ozcan Pinar Pelin, Serdengectı Mustafa, Koc Zehra Pinar, Balcı Yüksel, Tek Mesut, Bozlu Murat, Akbay Erdem, Erçolak Vehbi
Department of Nuclear Medicine, Mersin University, Faculty of Medicine, Mersin, Turkey.
Department of Nuclear Medicine, Aksaray University, Faculty of Medicine, Aksaray, Turkey.
World J Nucl Med. 2022 Jul 5;21(2):106-111. doi: 10.1055/s-0042-1750331. eCollection 2022 Jun.
Imaging plays an important role in the evaluation of prostate cancer patients. In recent years, much attention has been focused on gallium 68 prostate-specific membrane antigen positron emission tomography-computed tomography ( Ga PSMA PET-CT) in prostate cancer patients and has been widely used for staging, restaging, and therapy response for these patients. The aim of this study was to report Ga PSMA PET-CT in other cancers and benign processes incidentally detected on Ga PSMA PET-CT in patients with prostate cancer. A total of 600 Ga PSMA PET-CT scans were performed for initial staging, restaging, detection of suspected recurrence, and therapy response in prostate cancer patients between December 2018 and June 2020. A total of 38 patients with histopathologically proven prostate cancer were included in the current study with other malignancies and benign processes. Mainly histopathology in most of cases and clinical and radiological follow-up in few cases after PET/CT scanning served as the standard of reference. A total of 38 patients (age range: 52-85 years; mean age: 68.6) with prostate cancer final histopathology results were included in the study. A total of 51 lesion sites were evaluated in 38 patients. Forty-one lesion regions of these 51 regions were based on histopathological diagnosis, whereas 10 of them were based on clinical follow-up and conventional radiological follow-up as differential criteria. Thirty of 51 lesion regions were evaluated as malignant and 21 were benign lesions. The most common Ga PSMA ligand avid malignancy was lung adenocarcinoma (6/38). Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein and mainly expressed in prostate epithelium. Ga PSMA PET-CT imaging is very sensitive and specific imaging modality in prostate cancer patients. However, other malignancies and some benign processes may also have Ga PSMA ligand avidity and some prostate cancer metastases may imitate other malignancies.
影像学在前列腺癌患者的评估中起着重要作用。近年来，68镓前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描（68Ga PSMA PET-CT）在前列腺癌患者中备受关注，并已广泛用于这些患者的分期、再分期及治疗反应评估。本研究的目的是报告68Ga PSMA PET-CT在前列腺癌患者中偶然发现的其他癌症及良性病变中的情况。
2018年12月至2020年6月期间，共对600例前列腺癌患者进行了68Ga PSMA PET-CT扫描，用于初始分期、再分期、检测疑似复发及评估治疗反应。本研究纳入了38例经组织病理学证实患有前列腺癌且伴有其他恶性肿瘤及良性病变的患者。大多数病例主要以组织病理学为参考标准，少数病例在PET/CT扫描后以临床及影像学随访结果为参考标准。
本研究纳入了38例前列腺癌最终组织病理学结果的患者（年龄范围：52 - 85岁；平均年龄：68.6岁）。共对38例患者的51个病变部位进行了评估。这51个区域中的41个病变区域基于组织病理学诊断，而其中10个基于临床随访及传统影像学随访作为鉴别标准。51个病变区域中30个被评估为恶性，21个为良性病变。最常见的68Ga PSMA配体摄取阳性的恶性肿瘤是肺腺癌（6/38）。
前列腺特异性膜抗原（PSMA）是一种细胞表面糖蛋白，主要表达于前列腺上皮。68Ga PSMA PET-CT成像在前列腺癌患者中是一种非常敏感且特异的成像方式。然而，其他恶性肿瘤及一些良性病变也可能有68Ga PSMA配体摄取，且一些前列腺癌转移灶可能类似其他恶性肿瘤。
